Post hoc analysis of the glutamics–trial: intravenous glutamate infusion and use of inotropic drugs after cabg by Mårten Vidlund et al.
RESEARCH ARTICLE Open Access
Post hoc analysis of the glutamics–trial:
intravenous glutamate infusion and use of
inotropic drugs after cabg
Mårten Vidlund2, Bashir Tajik1, Erik Håkanson1, Örjan Friberg2, Jonas Holm1, Farkas Vanky1 and Rolf Svedjeholm1*
Abstract
Background: Intravenous glutamate reduced the risk of developing severe circulatory failure after isolated coronary
artery bypass graft surgery (CABG) for acute coronary syndrome (ACS) in a double-blind randomised clinical trial
(GLUTAMICS-ClinicalTrials.gov Identifier:NCT00489827). Here our aim was to study if glutamate was associated with
reduced the use of inotropes.
Methods: Post-hoc analysis of 824 patients undergoing isolated CABG for ACS in the GLUTAMICS-trial. ICU-records
were retrospectively scrutinised including hourly registration of inotropic drug infusion, dosage and total duration
during the operation and postoperatively.
Results: ICU-records were found for 171 out of 177 patients who received inotropes perioperatively. Only one
fourth of the patients treated with inotropes fulfilled study criteria for postoperative heart failure at weaning from
cardiopulmonary bypass (CPB) or later in the ICU. Inotropes were mainly given preemptively to facilitate weaning
from CPB or to treat postoperative circulatory instability (bleeding, hypovolaemia). Except for a significantly lower
use of epinephrine there were only trends towards lower need of other inotropes overall in the glutamate group.
In patients treated with inotropes (glutamate n = 17; placebo n = 13) who fulfilled study criteria for left ventricular
failure at weaning from CPB the average duration of inotropic treatment (34 ± 20 v 80 ± 77 h; p = 0.014) and the
number of inotropes used (1.35 ± 0.6 v 1.85 ± 0.7; p = 0.047) were lower in the glutamate group.
Conclusions: Intravenous glutamate was associated with a minor influence on inotrope use overall in patients
undergoing CABG for ACS whereas a considerable and significant reduction was observed in patients with heart
failure at weaning from CPB.
Keywords: Coronary artery bypass surgery, Intensive care, Postoperative complications, Inotropic drugs, Milrinone,
Epinephrine, Glutamate
Background
The GLUTAMICS-trial investigated if intravenous
glutamate infusion given in association with surgery for
acute coronary syndrome could prevent myocardial
injury, postoperative heart failure and reduce mortality
[1]. The study was negative with regard to the primary
endpoint, which was a composite of postoperative
mortality, perioperative myocardial infarction and left
ventricular failure at weaning from cardiopulmonary
bypass (CPB). However, intravenous glutamate reduced
the relative risk of developing severe circulatory failure
by more than 50 % in most high-risk groups. Patients
with heart failure at weaning from CPB required markedly
shorter ventilator treatment and ICU-stay if they were
treated with glutamate. These results are compatible with a
beneficial effect of glutamate on post-ischaemic myocardial
recovery after coronary artery bypass surgery (CABG).
However, it can be argued that other factors such as
differences in the use of inotropic drugs could have
explained the results. If glutamate enhances myocardial
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recovery in post-ischaemic heart failure one would
expect it to be accompanied by a reduced need for
inotropic drugs. The primary aim of this study was,
therefore, to investigate if intravenous glutamate
infusion influenced the use of inotropic drugs in patients
operated for acute coronary syndrome in the
GLUTAMICS-trial. The secondary aim was to investi-
gate if glutamate due to its suggested vasodilator proper-




This study is a post hoc analysis of a double-blind pro-
spective randomised clinical trial, the GLUTAMICS-trial
[1]. Inclusion criteria were CABG for acute coronary
syndrome. Patients were eligible for inclusion regardless
if the procedure was done on-pump or off-pump.
Exclusion criteria were: informed consent not possible
because of critical condition or other reason, age > 85 years,
body weight >125 kg; food allergy known to have caused
rash, flush or asthma; preoperative use of inotropic drugs
or mechanical circulatory assist, preoperative dialysis,
redo-procedure, unexpected intraoperative finding or event
that increased the magnitude of the procedure to over-
shadow the originally planned procedure.
The original trial was planned for 2214 patients but
the trial was terminated after 861 patients as prespeci-
fied stopping criteria per protocol were fulfilled at
interim analysis as previously reported [1]. For this par-
ticular analysis a small heterogeneous group of patients
having additional procedure to CABG was excluded
(Fig. 1). Eight hundred twenty four patients in the
GLUTAMICS-trial were operated with isolated CABG
for acute coronary syndrome between October 4, 2005
and November 12, 2009 at three Swedish Cardiac Sur-
gery Centres (University Hospital of Linköping, Örebro
Fig. 1 Flowchart of patient selection and presentation of results at three different levels
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University Hospital and Blekinge County Hospital in
Karlskrona).
Patients were randomised to blinded intravenous infu-
sion of 0.125 M glutamate or saline solution at a rate of
1.65 ml/kg body weight and hour started at the induc-
tion of anaesthesia and stopped 2.5 h after declamping
the aorta or when total of 500 ml had been infused.
Further details on the glutamate solution and the
GLUTAMICS-trial are given in the Additional file 1.
Patients receiving inotropes were identified by the aid
of the Case Report Form (CRF), the institutional database
and ICU-records. Use of inotropes was registered in the
CRF at weaning from CPB and on admission to ICU.
Furthermore, use of inotropes exceeding 30 min was
registered by the attending physicians in the institutional
database. Finally the ICU records of all patients staying
longer than 24 h were retrospectively investigated to
identify use of inotropes that had not been recorded in the
CRF or database. Complete ICU-records were found for
171 out of 177 patients who received inotropes during this
period (Fig. 1). These medical records were then scruti-
nised by an investigator (BT) previously not involved in
the GLUTAMICS-trial. Data retrieval included hourly
registration of inotropic drug infusion, dosage and total
duration intraoperatively and postoperatively.
Inotropic drugs used during the study period were
adrenaline, milrinone (Corotrop™), levosimendan (Sim-
dax™) and dopamine. Adrenaline and milrinone were the
most used drugs whereas levosimendan and dopamine
only were used in a small fraction. Therefore we present
the results for inotrope use overall and separately only
for adrenaline and milrinone treatment.
Noradrenaline was used liberally as a vasoconstrictor
and its dosages were registered for the first 15 postoper-
ative hours.
Definitions
Use of inotropes was defined as any use of inotropic
drugs (except noradrenaline) regardless of indication,
duration or dosage. Participating centres and individual
clinicians were free to institute inotropic drugs accord-
ing to their choice and usual practice.
Preemptive use of inotropic drugs to facilitate weaning
from CPB was defined as use of inotropic drugs before
weaning from CPB in patients that according to prespe-
cified criteria were deemed, by the blinded clinical
endpoints committee, not to have had heart failure at
weaning. If, however, the patient fulfilled prespecified
criteria for heart failure at weaning use of inotropes was
considered “treatment” regardless if the drugs had been
instituted before weaning or instituted because of
weaning problems.
Prespecified criteria were used by a blinded endpoints
committee to determine if heart failure was present.
Briefly clinical and echocardiographic signs of heart fail-
ure as a cause of low mixed venous oxygen saturation
(SvO2) were used to diagnose postoperative heart failure
[2–4]. A surgical pulmonary artery catheter was intro-
duced in all patients for sampling of SvO2 [2, 3]. SvO2
was measured in every patient at weaning from CPB, 5
min after protamine administration and on admission to
ICU and whenever clinical condition of the patients
required evaluation of the haemodynamic status. If the
rare cases when a patient required more meticulous moni-
toring to guide haemodynamic treatment a Swan-Ganz
catheter was employed. Detailed criteria are given in the
Additional file 1.
Postoperative heart failure was categorised into heart
failure evident at weaning from cardiopulmonary bypass
or late circulatory failure presenting after apparently un-
complicated weaning. Circulatory failure was classified
as late if it became evident after weaning from CPB and
it was categorised as cardiac or non-cardiac in origin.
Severe circulatory failure was defined as heart failure
leading to death or requiring ICU stay ≥ 48 h with intra-
aortic balloon pump for ≥24 h or inotropic agents in
dosages according to Additional file 1 for ≥24 h.
Postoperative mortality was defined as death within
30 days of surgery. Hospital mortality was defined as
death during the first hospitalisation period including
stay at the referral hospital after discharge postopera-
tively. Cardiac cause of death was assessed by the end-
points committee.
Statistics
Two-sided Fisher’s exact test was used was used for
comparison of dichotomous variables. Two-sided Students
t-test or Mann-Whitney U test as appropriate were used
for comparison of continuous variables. Statistical signifi-
cance was defined as p < 0.05. The data are given as
percentages or means ± standard deviation.
Results
Preoperative data
Preoperative data for patients undergoing isolated CABG
for acute coronary syndrome in the GLUTAMICS-trial
is given in Table 1. Despite randomisation there were
minor differences with significantly more patients having
left main stenosis and extra-cardiac arterial disease in
the glutamate group. There was also a trend toward a
higher risk profile according to EuroSCORE in the
glutamate group.
Intraoperative data
Intraoperative data for patients undergoing isolated CABG
for acute coronary syndrome in the GLUTAMICS-trial is
given in Table 1. No significant differences between the
groups were observed.
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Table 1 Preoperative, intraoperative and postoperative data in patients undergoing isolated CABG for acute coronary syndrome in
the GLUTAMICS-trial
Placebo n = 413 Glutamate n = 411 p-value
Preoperative data
Age (years) 68 ± 9 68 ± 9 0.30
Female 18.9 % 17.5 % 0.65
Weight (kg) 83 ± 15 81 ± 14 0.25
Length (cm) 173 ± 8 173 ± 8 0.59
BMI (kg/m2) 27 ± 4 27 ± 4 0.10
B-Hb (g/l) 137 ± 14 137 ± 14 0.68
p-Creatinine (μmol/l) 97 ± 29 98 ± 27 0.60
Hypertension 60 % 56 % 0.29
COPD 5.1 % 7.9 % 0.09
Diabetes 26 % 24 % 0.50
Extra-cardiac arterial disease 9 % 14 % 0.049
CCS class IV angina 56 % 55 % 0.73
Left main stem stenosis 34 % 42 % 0.02
Myocardial Infarct < 24 h 1.2 % 0.2 % 0.22
Moderate-Severe LV-dysfunction 18.6 % 18.0 % 0.86
EuroSCORE 4.9 ± 2.7 5.2 ± 2.7 0.10
Intraoperative data
Number of bypasses 3.9 ± 1.1 4.1 ± 1.0 0.18
Cross-clamp time (min) 52 ± 18 51 ± 18 0.51
CPB time (min) 80 ± 25 81 ± 28 0.61
Indications for inotropes
Preemptively before weaning from CPB 9.0 % 9.7 % 0.81
LV-failure at weaning from CPB 3.4 % 4.4 % 0.48
Late onset cardiac failure 1.9 % 1.9 % 1.0
Cardiac failure postoperatively (total) 5.3 % 6.3 % 0.54
Late circulatory failure non-cardiac 3.4 % 1.5 % 0.11
Other 0.9 % 5.4 % 0.001
Circulatory treatment
Inotropes (total) 18.6 % 22.9 % 0.15
Adrenaline 11.9 % 16.1 % 0.09
Milrinone 9.4 % 9.0 % 0.90
Levosimendane 3.6 % 3.4 % 1.0
Dopamine 1.7 % 2.7 % 0.35
Intra-aortic balloon pump 1.2 % 0 % 0.06
Postoperative outcome
Time on ventilator (h) 13 ± 54 10 ± 37 0.35
ICU stay (h) 31 ± 58 30 ± 52 0.77
Severe circulatory failure 3.9 % 1.5 % 0.049
Stroke within 24 (h) 1.5 % 1.0 % 0.53
Cardiac mortality 0.7 % 0.2 % 0.62
30 days mortality 1.0 % 0.7 % 0.71
Hospital mortality 1.2 % 1.2 % 0.74
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Postoperative data
Postoperative data for patients undergoing isolated CABG
for acute coronary syndrome in the GLUTAMICS-trial is
given in Table 1. The incidence of severe circulatory
failure was significantly lower in the glutamate group
(1.5 % v 3.9 %; p = 0.049).
Postoperative data for all patients treated with ino-
tropes after isolated CABG for acute coronary syndrome
in the GLUTAMICS-trial is given in Table 2. The inci-
dences of severe circulatory failure (6.2 % v 17.5 %; p =
0.03) and the need for intra-aortic balloon pump (0 % v
5.2 %; p = 0.04) were significantly lower in the glutamate
group.
Postoperative data for patients treated with inotropes
because of heart failure at weaning from CPB after
isolated CABG for acute coronary syndrome in the
GLUTAMICS-trial is given in Table 3. Glutamate treated
patients had a significantly lower incidence of severe
circulatory failure (11.8 % v 61.5 %; p = 0.007), shorter
ventilator treatment and shorter stay in the ICU.
Table 1 Preoperative, intraoperative and postoperative data in patients undergoing isolated CABG for acute coronary syndrome in
the GLUTAMICS-trial (Continued)
Postoperative outcome
Time on ventilator (h) 13 ± 54 10 ± 37 0.35
ICU stay (h) 31 ± 58 30 ± 52 0.77
Severe circulatory failure 3.9 % 1.5 % 0.049
Stroke within 24 (h) 1.5 % 1.0 % 0.53
BMI body mass index, COPD chronic obstructive pulmonary disease, LV left ventricular, CPB cardiopulmonary bypass, ICU, intensive care unit
Table 2 Circulatory treatment and postoperative outcome in all patients treated with inotropes
Placebo n = 77 Glutamate n = 94 p-value
Circulatory treatment
Inotropes (total) 100 % 100 %
Inotropes duration (hours) 38 ± 46 29 ± 30 0.14
Number of inotropes 1.4 ± 0.6 1.3 ± 0.6 0.45
Adrenaline 63.6 % 70.2 % 0.41
Adrenaline duration (hours)a 28 ± 49 17 ± 25 0.049
Adrenaline duration (hours)b 44 ± 55 24 ± 27 0.01
Average max dosage μg/kg/minb 0.028 ± 0.016 0.028 ± 0.020 0.94
Milrinone 50.6 % 39.4 % 0.16
Milrinone duration (hours)a 14 ± 25 9 ± 19 0.14
Milrinone duration (hours)b 27 ± 30 22 ± 25 0.44
Average max dosage μg/kg/minb 0.40 ± 0.14 0.36 ± 0.12 0.28
Noradrenaline 71.4 % 70.2 % 1.0
Average max dosage μg/kg/mina 0.084 ± 0.093 0.068 ± 0.089 0.24
Average max dosage μg/kg/minb 0.118 ± 0.090 0.097 ± 0.092 0.20
IABP 5.2 % 0 % 0.04
Postoperative outcome
Time on ventilator (hours) 34 ± 95 26 ± 74 0.54
ICU stay (hours) 63 ± 98 59 ± 78 0.79
Severe circulatory failure 17.5 % 6.2 % 0.03
Stroke within 24 h 2.6 % 3.2 % 1.0
Cardiac mortality 2.6 % 1.1 % 0.59
30 day mortality 1.3 % 2.1 % 1.0
Hospital mortality 2.6 % 3.2 % 1.0
IABP intra-aortic balloon pump, ICU intensive care unit
aaverage for all patients treated with inotropes
baverage for patients treated with specific drug
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Inotrope use
ICU-records were found for 171 out of 177 patients who
received inotropes perioperatively. Details of inotrope
use are given in Tables 1, 2 and 3. Only one fourth of
patients treated with inotropes fulfilled study criteria for
postoperative heart failure at weaning from CPB or later
in the ICU. The other main indications to give inotropes
were preemptive administration to facilitate weaning
from CPB or to treat postoperative circulatory instability
(bleeding, hypovolaemia). Except for a significantly lower
use of adrenaline there were only trends towards lower
need of other inotropes overall in the glutamate group
(Tables 1 and 2).
In patients who fulfilled criteria for left ventricular
failure at weaning from CPB (glutamate n = 17; placebo
n = 13) the average duration of inotropic treatment (34
± 20 v 80 ± 77 h; p = 0.014) and the number of inotropes
administered (1.35 ± 0.6 v 1.85 ± 0.7; p = 0.04) were lower
in the glutamate group (Table 3).
Vasoconstrictor use
Details of noradrenaline use during the first 15 postoper-
ative hours in patients treated with inotropes are given
in Tables 2 and 3. In patients treated with inotropes
71 % in the control group and 70 % in the glutamate
group also received noradrenaline. The maximum dos-
age given did not differ significantly between the groups.
Noradrenaline requirements were lower in the glutamate
group among patients with heart failure at weaning from
CPB (Table 3).
Discussion
This post-hoc analysis of the GLUTAMICS-trial de-
monstrates that glutamate treatment was associated with
a reduced use of inotropes in patients with heart failure
at weaning from CPB. Glutamate infusion was not
associated with an increased need for vasoconstrictors
suggesting that any vasodilator properties of glutamate
in the dosage used is limited.
Table 3 Circulatory treatment and postoperative outcome in patients treated with inotropes because of heart failure on weaning
from CPB
Placebo n = 13 Glutamate n = 17 p-value
Inotropes (total) 100 % 100 % 1.0
Inotropic duration (hours)a 85 ± 77 34 ± 20 0.014
Number of inotropes 1.8 ± 0.7 1.3 ± 0.6 0.04
Adrenaline 85 % 88 % 1.0
Adrenalin duration (hours)a 78 ± 82 25 ± 19 0.016
Adrenalin duration (hours)b 92 ± 82 28 ± 17 0.007
Average max dosage μg/kg/minb 0.031 ± 0.012 0.029 ± 0.030 0.73
Milrinone 54 % 35 % 0.46
Milrinone duration (hours)a 33 ± 52 9 ± 14 0.09
Milrinone duration (hours)b 60 ± 60 27 ± 8 0.20
Average max dosage μg/kg/minb 0.38 ± 0.15 0.36 ± 0.02 0.78
Noradrenaline 85 % 59 % 0.23
Average max dosage μg/kg/mina 0.089 ± 0.096 0.034 ± 0.033 0.03
Average max dosage μg/kg/minb 0.106 ± 0.095 0.058 ± 0.022 0.14
IABP 31 % 0 % 0.03
Postoperative outcome
Time on ventilator (hours) 109 ± 192 6 ± 3 0.033
Time on ventilator >48 h 46 % 0.0 % 0.003
ICU stay (hours) 150 ± 186 45 ± 38 0.031
Severe circulatory failure 61.5 % 11.8 % 0.007
Stroke within 24 h 0.0 % 0.0 % 1.0
Cardiac mortality 15.4 % 5.9 % 0.56
30 day mortality 15.4 % 5.9 % 0.56
Hospital mortality 15.4 % 5.9 % 0.56
IABP intra-aortic balloon pump, ICU intensive care unit
aaverage for all patients treated with inotropes
baverage for patients treated with specific drug
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Postoperative heart failure or low cardiac output
syndrome is the major cause for morbidity and mortality
in cardiac surgery [5–8]. Already in the beginning of heart
surgery it was noted that early death after cardiac surgery
was related to low cardiac output postoperatively [9].
Although the hazards of low cardiac output syndrome
have been known for a long time, there is no consensus
on how to define postoperative heart failure. Furthermore,
there are no generally accepted guidelines for treatment of
postoperative heart failure [10–12]. Different strategies for
treatment with inotropic, metabolic and mechanical
support depend on local clinical practice or are up to the
discretion of the individual physician [12].
Inotropic drugs improve cardiac output but this is
achieved at the price of a marked increase in myocardial
workload and oxygen consumption [13]. In the early
postoperative period after cardiac surgery the heart is in a
vulnerable state recovering from ischaemia [14, 15]. Ino-
tropic agents can aggravate the consequences of ischaemia
[16]. It has been shown that ischaemia and evolving myo-
cardial infarction account for a large proportion of post-
operative heart failure after CABG [6, 17].
The role of inotropes in cardiac surgery is therefore
controversial [12]. Some authors claim that liberal use of
inotropes and goal-directed haemodynamic therapy can
improve outcome whereas other have reported that
liberal use of inotropes was associated with increased
morbidity and mortality [12, 18–20].
In clinical practice the use of inotropes in cardiac sur-
gery varies much between different institutions and differ-
ent physicians as evidence-based guidelines are lacking. In
the present study only one fourth of the patients treated
with inotropes fulfilled study criteria for heart failure.
Several biochemical mechanisms by which glutamate
could influence outcome after myocardial ischaemia
have been described [21–24]. Glutamate could enhance
myocardial tolerance to ischemia by its role in the
malate-aspartate shuttle transporting reducing equiva-
lents across the mitochondrial membrane, thus facilitat-
ing anaerobic glycolysis by regulating the NAD/NADH
balance in the cytosol. Glutamate also contributes to an
alternative anaerobic pathway for regeneration of high-
energy phosphates in the mitochondria by substrate level
phosphorylation. Glutamate improves clearance of
lactate and NH3 by taking part in reactions involving
transamination of pyruvate to alanine and glutamate to
glutamine. Glutamate could stimulate post-ischaemic
recovery of myocardial oxidative metabolism and func-
tion due to its anaplerotic role; glutamate plays a key
role for replenishment of Krebs cycle intermediates lost
during ischaemia [21–24].
In animal in vitro and in vivo models numerous studies
have shown that glutamate protects the myocardium from
ischaemia and promotes recovery of oxidative metabolism
after ischaemia [21, 25–27]. In humans intravenous
glutamate infusion has been shown to promote metabolic
and haemodynamic recovery after cardiac surgery [28, 29].
Promoting metabolic and functional recovery with
metabolic support represents a novel concept in the treat-
ment of heart failure after acute ischaemia. Intravenous
glutamate improved metabolic and haemodynamic recov-
ery early after CABG [28, 29]. Early clinical experience
with intravenous metabolic support showed that the need
for inotropes could almost be abolished while clinical out-
comes with regard to postoperative mortality, postopera-
tive renal dysfunction and long-term survival compared
favourably with literature [4]. This encouraging experience
contributed to the initiation of the GLUTAMICS-trial.
The GLUTAMICS-trial was negative with regard to
the primary endpoint [1]. However, the study included a
high proportion of low risk patients and furthermore the
design of the primary endpoint suffered from liberal
preemptive use of inotropes in patients anticipated to
have weaning problems. It became evident at clinical
endpoint committee meetings that preemptive use of
inotropes prevented detection of weaning problems in
patients who later developed severe circulatory failure.
The secondary endpoint severe circulatory failure
discriminated mild short-lasting heart failure at weaning
from cardiopulmonary bypass from clinically significant
heart failure requiring substantial circulatory support
and leading to prolonged ICU stay or death. In the
glutamate treated patients the relative risk of developing
severe circulatory failure was reduced by more than
50 % in most risk groups undergoing isolated CABG [1].
For those who believe that inotropes are beneficial after
cardiac surgery the present post-hoc analysis clearly
shows that these results were not explained by more lib-
eral use of inotropes in the glutamate group. On the
contrary, glutamate infusion was associated with a re-
duced need for inotropes in patients fulfilling criteria for
heart failure on weaning from CPB, which is compatible
with the suggested mechanism of glutamate, i.e. to pro-
mote post-ischaemic recovery of the heart. These results
also agree with previous clinical experience, which has
showed that metabolic support can achieve excellent clin-
ical outcomes with reduced need for inotropes [4]. The
fact that glutamate had a minor impact on inotrope use
overall is not unexpected given that only about one fourth
of the patients treated fulfilled criteria for heart failure.
This post-hoc analysis is unique as it, to our knowledge,
is the first to provide a detailed investigation on the hourly
use of inotropes and vasoconstrictors postoperatively after
cardiac surgery. The major limitation is the nature of the
study. Post-hoc analyses should always be interpreted
cautiously. The criteria used for postoperative heart failure
in the GLUTAMICS-trial are inevitably debatable. Al-
though this condition is a major cause for postoperative
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mortality generally accepted criteria for this diagnosis are
lacking. To address this issue the investigators had based
the criteria on variables documented with regard to
outcome and provided the blinded clinical endpoints
committee with strict prespecified criteria to minimise
bias from individual clinical judgement [1–3].
A potential hazard of glutamate is that it acts as an exci-
totoxin, which could contribute to neurological damage
under certain conditions. However, no increase in clinically
evident neurological injury has been observed when
glutamate enhanced cardioplegic solutions or intravenous
infusions have been used in clinical practice [30, 31]. We
could not detect any evidence for subclinical neurological
injury associated with intravenous glutamate in the S-100B
substudy of the GLUTAMICS-trial [32]. Another concern
has been suggested vasodilator properties occasionally
observed in association with glutamate enriched blood
cardioplegia. In this post-hoc analysis no increase in the
need for vasoconstrictors were observed with the dosage of
glutamate used during first 15 postoperative hours when
the effect of glutamate should have subsided. With the
infusion rate used a decrease to normal blood levels of glu-
tamate has been observed within 30 min after discontinu-
ation of the infusion [33]. Thus, it appears that intravenous
glutamate infusions in the dosages employed can be safely
administered to patients undergoing cardiac surgery.
Conclusions
Intravenous glutamate was associated a minor effect on
inotrope use overall in patients undergoing CABG for
acute coronary syndrome whereas a considerable and
significant reduction was observed in patients with heart
failure at weaning from CPB. Only about one fourth of
the patients treated with inotropes in the GLUTAMICS-
trial fulfilled criteria for heart failure.
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